On Jul. 17, 2006, the SERM drug raloxifene (Evista) was found to reduce breast cancer risk for postmenopausal women who have higher risk.

Raloxifene therapy was associated with a reduced risk of invasive breast cancer in postmenopausal women irrespective of the presence/absence of risk factors; its effect was greater in women with a family history of breast cancer.